Psychosis - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 70
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P04F168C4F3EN
Leaflet:

Download PDF Leaflet

Psychosis - Pipeline Review, H2 2016
Psychosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psychosis - Pipeline Review, H2 2016, provides an overview of the Psychosis (Central Nervous System) pipeline landscape.

Psychosis is a serious mental disorder characterized by thinking and emotions that are so impaired, that they indicate that the person experiencing them has lost contact with reality. Psychotic symptoms include disorganized thought, speech or behavior, disordered thinking (jumping between unrelated topics, making strange connections between thoughts), Catatonia (unresponsiveness). Treatment includes antipsychotic drugs, which reduce hallucinations and delusions and improve thinking and behavior are helpful, whether the cause is a medical or psychiatric disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psychosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psychosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psychosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15 and 1 respectively for Psychosis.

Psychosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psychosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Psychosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psychosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psychosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psychosis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psychosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psychosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Psychosis Overview
Therapeutics Development
Pipeline Products for Psychosis - Overview
Psychosis - Therapeutics under Development by Companies
Psychosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Psychosis - Products under Development by Companies
Psychosis - Companies Involved in Therapeutics Development
Acadia Pharmaceuticals Inc.
Addex Therapeutics Ltd
Evotec AG
Gabather AB
Glenmark Pharmaceuticals Ltd.
Heptares Therapeutics Limited
Integrative Research Laboratories Sweden AB
Merck & Co., Inc.
Newron Pharmaceuticals S.p.A.
Reviva Pharmaceuticals Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc.
Psychosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-0306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
evenamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HUF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRL-790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pimavanserin tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEP-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Psychosis - Dormant Projects
Psychosis - Discontinued Products
Psychosis - Product Development Milestones
Featured News & Press Releases
May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch
Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 70

LIST OF TABLES

Number of Products under Development for Psychosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
Psychosis - Pipeline by Addex Therapeutics Ltd, H2 2016
Psychosis - Pipeline by Evotec AG, H2 2016
Psychosis - Pipeline by Gabather AB, H2 2016
Psychosis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Psychosis - Pipeline by Heptares Therapeutics Limited, H2 2016
Psychosis - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
Psychosis - Pipeline by Merck & Co., Inc., H2 2016
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Psychosis - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Psychosis - Dormant Projects, H2 2016
Psychosis - Discontinued Products, H2 2016 61

LIST OF FIGURES

Number of Products under Development for Psychosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Psychosis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 69 pages
Evotec AG - Product Pipeline Review - 2016 US$ 1,275.00 Apr, 2016 · 60 pages

Ask Your Question

Psychosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: